Research from Japan documenting remarkable survival rates among patients with inoperable lung cancer may only hint at the potential of proton-beam radiation therapy. The study out of the Proton Medical Research Center in Tennoudai, Japan, documented high survival rates for 55 patients suffering from stage I inoperable non-small-cell lung cancer.
Thirty-five patients with stage II-IIIb NSCLC were treated from November 2001 to July 2008 with different doses. Peripherally and centrally located tumors were irradiated with a median proton dose of 78.3 Gy.
The two-year progression-free survival (PFS) rate among the stage I patients was 88.7% and the local control rate was 97%, the authors, led by Hidetsugu Nakayama, MD, PhD, reported.
Local (PFS) for stage II-III patients was 93.3% at one year and 65.9% at two years during a median observation period of 16.9 months. Local recurrence took place in 11.4% of patients with 37.1% developing regional recurrence, and 20% developing distant metastases. The PFS for stage II-III patients was 59.6% at one year and 29.2% at two years. The overall survival rate of stage II-III patients was 81.8% at one year and 58.9% at two years. A total of 42.9% developed grade 1 toxicities and 17.1% developed grade 2 toxicities. There were no cases of grade 3 or greater toxicities, the authors said (Int J Radiat Oncol Biol Phys online, September 30, 2010).
These rates contrast starkly with reported overall survival rates at five years for NSCLC patients treated with conventional radiotherapy, ranging from 6% to 31.4%. The difference may be due in part to the follow-up time differences in the available data: Two years for proton-beam radiation therapy and five for conventional therapy. But even for those treated with stereotactic radiosurgery, a highly precise form of radiation therapy, the survival rate is just is 54.7% after two years.
Reports of success with proton-beam therapy have seemed almost anecdotal because of the relatively few sites that offer this type of therapy. Much of the work has focused on cancers of the prostate and brain. But lately, with the rising number of proton-beam centers in the U.S. and around the world, other applications are being tried.
More research is needed to compare the relative effectiveness of proton-beam and stereotactic radiosurgery, the Japanese investigators said, just in regard to patients with stage I inoperable NSCLC. They urged a randomized clinical trial to clarify the survival benefit that might be achieved from using proton-beam radiation therapy.